Clinical Trial: SLV-324 Treatment of Metastatic Solid Tumors

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07108114) titled 'SLV-324 Treatment of Metastatic Solid Tumors' on July 24.

Brief Summary: This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-324 across a range of dose levels when administered to subjects with metastatic solid tumors.

Study Start Date: Aug., 2025

Study Type: INTERVENTIONAL

Condition: Metastatic Solid Tumors

Intervention: DRUG: SLV-324 intravenous (IV infusion)

SLV-324 will be administered as an IV infusion

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Solve Therapeutics

Disclaimer: Curated by HT Syndication....